The company approached us, that leaves the leverage in our hands.

Depending on what exactly we give up in scope, will determine if our return is worth it.

Do those bullet points have you fired up, because you can put me down has pretty underwhelmed.

I’m waiting for the final language on the scope stuff, but it better be a pretty small ask from the company.


- cares 2 is gonna get a vote in the next week
- moderna gets approval today and they have twice as many doses ready to go than Pfizer.


Sent from my iPhone using Tapatalk